Product category:
Laboratory and scientific books and publishing
News Release from: Frost and Sullivan | Subject: A776
Edited by the Laboratorytalk Editorial
Team on 01 April 2004
Strategic analysis of world DNA
microarray markets
Accompanying the rising popularity of microarrays as diagnostic tools, there has been constant demand from consumers for standardised and integrated solutions
Compared to the total research products market, the DNA microarray market continues to experience robust growth world wide, reveals new analysis by Frost and Sullivan Despite a slowdown in instrument sales, sale of research consumables continues to register marked growth due to a strongly installed base
This article was originally published on Laboratorytalk on 2 Aug 2002 at 8.00am (UK)
Related stories
Smart materials: the new frontier of technology
Analysis reveals the advances made in the development of industrial applications for smart, active, or engineered materials, including their use in smart structures
Ready for convergence?
The convergence of nanotechnology, biotechnology, information technology, and cognitive science will have a substantial impact on companies and markets in the future
Currently, the market includes both commercial and 'homebrew' (self-printed) products; however, it is expected that commercial products will dominate the future market.
For the both segments to reach the success phase, companies need to anticipate the trends in the market, successfully counter threats, and develop solutions that meet and define the customers' needs.
Accompanying the rising popularity of microarrays as diagnostic tools, there has been constant demand from consumers for standardised and integrated solutions.
Further reading
European cardiac risk assessment markers
Elevated European CHF mortality rates and introduction of premium-priced assays stimulate uptake of cardiac risk assessment markers, according to new research
Bubble bursts in defoamer market
Negative growth will force European pulp and paper defoamer suppliers to recognise commodity market, says new report
Banking on blood
The blood banking devices market will continue to post steady figures, aided by the industry's flexibility and adaptability to changing market needs and technological advancements
In keeping with this, vendors are offering solutions that incorporate multiple products such as arrayers, readers, software, slides and content.
Future solutions are expected to integrate a scanner, software, and hybridisation equipment.
"Standardisation of content is also likely to overcome the difficulty of comparing data across varied platforms," says industry analyst Isaac Meek from Frost and Sullivan.
This process is set to be aided by development of arrays that identify and monitor the transcriptional profile of different splice variants.
The use of DNA microarrays in pharmaceutical and biotechnology segments, especially in clinical studies is being challenged by the slow growth of the pharmaceutical markets.
This can be overcome by forming mutually beneficial partnerships with pharmaceutical and biotech companies and chalking out effective marketing strategies, which explain benefits to potential new users.
Sales can also be boosted by offering convenient price breaks, attractive packages, and services.
The global market for DNA microarrays is poised to grow at an annual average of 6.7% from $596 million in 2003 to $937 million in 2010.
The commercial DNA microarray segment, which currently accounts for approximately 57% of the market revenues, is projected to grow faster than the self-printed segment as a result of increased adoption of standardised platforms.
However, revenue contributions of consumable and pre-printed arrays to the total market are likely to improve.
Though the US market continues to be the largest in terms of volume and revenues, the European market is experiencing substantial growth in the commercial array segment.
A significant amount of research is being conducted in Europe creating market growth opportunities.
As the market for microarrays matures, ample opportunities exist in clinical trials and diagnostics.
Increasing availability and validity of content, the success of the technology in offering high throughput capabilities that enable comprehensive studies and the promise of personalised medicine and enhanced knowledge of disease is also likely to encourage the uptake of microarrays as a diagnostic tool.
"The success of gene expression analysis has also sparked the employment of microarrays in non-traditional research areas such as agriculture and environmental science," notes Meek.
From a competitive viewpoint, consolidation of this highly competitive and fragmented market is likely to help larger microarray companies boost revenues.
Competitive success will hinge on the ability to offer complete solutions and develop open platforms.
• Frost and Sullivan: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
